viewAusCann Group Holdings Ltd
This purchase follows recent buying from the company’s board’s chairman.
’s () interim CEO and director Paul MacLeman has purchased 30,268 shares priced at 33 cents each via on-market trades.
MacLeman is an experienced pharmaceutical executive and was appointed to the company’s board in September 2018.
This is MacLeman’s first purchase of company shares.
READ: AusCann Group chairman buys $58,238 worth of shares on-market
In late February 2019, AusCann appointed global pharmaceutical business executive Ido Kanyon as its CEO commencing 22 May 2019.
Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at multi-billion dollar Ltd (NYSE:TEVA).
ASX:AC8
Market: ASX
Market Cap: $93.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Auscann targeting pain management with Australian cannabinoid products
Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....
on 09/05/2018
2 min read
Prev article
2 min read
